A Phase 1, Open-Label, Single Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of MEDI0382 in Subjects With Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 04 May 2018
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors MedImmune
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Apr 2018 Planned End Date changed from 27 Apr 2018 to 24 Apr 2018.
- 06 Apr 2018 Planned primary completion date changed from 27 Apr 2018 to 24 Apr 2018.